These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 19656705)
1. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Li J; Munsiff SS; Tarantino T; Dorsinville M Int J Infect Dis; 2010 Apr; 14(4):e292-7. PubMed ID: 19656705 [TBL] [Abstract][Full Text] [Related]
2. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Li J; Munsiff SS; Driver CR; Sackoff J Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767 [TBL] [Abstract][Full Text] [Related]
3. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Anger HA; Proops D; Harris TG; Li J; Kreiswirth BN; Shashkina E; Ahuja SD Clin Infect Dis; 2012 May; 54(9):1287-95. PubMed ID: 22412056 [TBL] [Abstract][Full Text] [Related]
4. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347 [TBL] [Abstract][Full Text] [Related]
5. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Machado A; Finkmoore B; Emodi K; Takenami I; Barbosa T; Tavares M; Reis MG; Arruda S; Riley LW Int J Tuberc Lung Dis; 2009 Jun; 13(6):719-25. PubMed ID: 19460247 [TBL] [Abstract][Full Text] [Related]
7. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Anibarro L; Casas S; Paz-Esquete J; Gonzalez L; Pena A; Guerra MR; Sande D; Calviño L; Santin M; Int J Tuberc Lung Dis; 2010 Jun; 14(6):701-7. PubMed ID: 20487607 [TBL] [Abstract][Full Text] [Related]
8. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Ziakas PD; Mylonakis E Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936 [TBL] [Abstract][Full Text] [Related]
9. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Hoopes AJ; Kammerer JS; Harrington TA; Ijaz K; Armstrong LR Arch Intern Med; 2008 Oct; 168(18):1984-92. PubMed ID: 18852399 [TBL] [Abstract][Full Text] [Related]
10. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics. Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147 [TBL] [Abstract][Full Text] [Related]
12. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. Diaz A; Diez M; Bleda MJ; Aldamiz M; Camafort M; Camino X; Cepeda C; Costa A; Ferrero O; Geijo P; Iribarren JA; Moreno S; Moreno ME; Labarga P; Pinilla J; Portu J; Pulido F; Rosa C; SantamarÃa JM; Telenti M; Trapiella L; Trastoy M; Viciana P BMC Infect Dis; 2010 Sep; 10():267. PubMed ID: 20840743 [TBL] [Abstract][Full Text] [Related]
13. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Macaraig MM; Jalees M; Lam C; Burzynski J Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415 [TBL] [Abstract][Full Text] [Related]
14. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755 [TBL] [Abstract][Full Text] [Related]
15. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137 [TBL] [Abstract][Full Text] [Related]
16. [Accessibility and compliance of Ethiopian immigrants to latent tuberculosis infection treatment]. Bishara H; Ore L; Bshara H; Vinitsky O; Armaly N; Weiler-Ravell D Harefuah; 2014 Jan; 153(1):8-11, 66. PubMed ID: 24605398 [TBL] [Abstract][Full Text] [Related]
17. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696 [TBL] [Abstract][Full Text] [Related]
18. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS. Gutierrez EB; Gomes V; Picone CM; Suga H; Atomiya AN HIV Med; 2009 Oct; 10(9):564-72. PubMed ID: 19785665 [TBL] [Abstract][Full Text] [Related]
19. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in Southeast Asian refugees and migrants: completion and compliance are major determinants of effectiveness. MacIntyre CR; Ansari MZ; Carnie J; Hart WG Prev Med; 2000 May; 30(5):425-32. PubMed ID: 10845752 [TBL] [Abstract][Full Text] [Related]